History

Founded in 1997 based on research at the Norwegian Cancer Hospital. Transforming from a technology platform based company to a specialty pharma – The Bladder Cancer Company.

Photocure was founded by the Norwegian Radium Hospital to develop and commercialize a promising photodynamic non-melanoma skin cancer product with a vision to become a global leader in photodynamic technology.

Today Photocure is focusing on bladder cancer with the aim to deliver transformative solutions to improve the lives of bladder cancer patients. We operate in Europe and the U.S. with approximately 100 highly skilled employees and through partners in other territories.

2021

  • Hexvix® licensed to Asieris Meditech Co. Ltd for Mainland China & Taiwan
  • Photocure opens its European Head Office in Düsseldorf, Germany.
  • Regulatory approval of Hexvix® in Chile

2020

  • Photocure retrieves the rights to commercialize Hexvix® in European markets, from Ipsen.
  • Genotests SpA appointed as exclusive partner for Hexvix in Chile

2019

  • Cevira® out-licensed to Asieris Meditech Co., Ltd

2018

  • New CEO appointed - Dan Schneider
  • FDA Approval of expanded Indications for Blue Light Cystoscopy with Cysview®
  • Starting exclusive Nordic distribution of HIVEC® for Combat Medical

2017

  • Photocure files supplemental New Drug Application with FDA for Blue Light Cystoscopy (BLC®) with Cysview®
  • Allumera® divested to Bellus

2016

  • Blue light cystoscopy with Hexvix®/Cysview® recommended in the new AUA/SUO guidelines
  • Hexvix® marketing authorization approval in Australia
  • Hexvix® granted EU approval for prefilled syringe product packaging

2015

  • Hexvix® licensed by Juno Pharmaceuticals in Australia and New Zealand
  • Cysview® licensed by BioSyent Pharma in Canada
  • Hexvix® recommended in NICE Guidelines, UK

2014

  • Licensing agreement with Salix terminated

2013

  • Positive results of phase 2b Cevira® study

2012

  • Cysview® launch by Photocure in the U.S.
  • Exit Allumera® U.S. business

2011

  • Allumera® launched in the U.S.
  • Hexvix® licensed to Ipsen Pharma for all territories in the world except U.S. and Nordics

2010

  • Photocure Inc. established in the U.S.
  • Lumacan® licensed to Salix
  • Cysview® approved in the U.S.

2009

  • Metvix®/Aktilite® divested to Galderma S.A.
  • 2008 Metvix®/Aktilite® approved in the U.S.
  • PCI Biotech divested from Photocure

2008

  • Metvix®/Aktilite® approved in the U.S.
  • Completion of pivotal phase III study for Cysview® U.S. submission

2006

  • Hexvix® licensed to GE Healthcare
  • Hexvix® launched in the EU

2005

  • Hexvix® launched in the Nordics

2004

  • First approval for Hexvix®

2003

  • Galderma S.A launches Metvix®.

2002

  • Metvix® launched in the Nordics

2001

  • Metvix® licensed to Galderma S.A.
  • First approval for Metvix®

2000

  • Listed in the Oslo Stock Exchange (OSE)

1997

  • First full-time employee